CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Ombitasvir/Paritaprevir/Ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02219503
NCT02219503Phase 3Completed
CompareCT.gov

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

AbbVie·interventional·Posted Aug 19, 2014·Updated Jul 12, 2021

In Brief

A Phase 3 clinical trial evaluating Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection and Compensated Cirrhosis. Completed, enrolled 60 participants.

Detailed Summary

The purpose of this study was to evaluate the safety and efficacy of ombitasvir/ paritaprevir/ ritonavir and dasabuvir in adults with genotype 1b chronic hepatitis C virus (HCV) infection and cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection, Compensated Cirrhosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 19, 2014
Enrollment StartSep 1, 2014
Primary CompletionJun 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.9 years ago

Interventions

Ombitasvir/Paritaprevir/Ritonavirdrug

Tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Dasabuvirdrug

Tablet